Despite the promising theoretical framework suggesting the potential of targeting IL-1β for sepsis treatment, clinical trials involving anakinra, an IL-1β receptor antagonist, have not demonstrated a significant improvement in patient outcomes. This evidence concerns the gene IL1B and Sepsis.